Evidence map›Paper›PMID 41384078›Full record

ArticleRSC advances2025

Doxorubicin drug delivery using an electrospun nanofiber membrane of chitosan-polycaprolactone with metal-organic framework: Box-Behnken optimization, anticancer treatment, and antimicrobial activity.

Fahad T Alotaibi, Malak A Alamri, Lina M Alneghery, Ali M Alaseem, Mohamed G El-Desouky, Ashraf A El-Bindary

Abstract read
In one paragraph

Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fahad T AlotaibiDepartment of Anatomy and Physiology, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU) Riyadh 13317 Saudi Arabia.
Malak A AlamriHealth Sciences Research Center (HSRC), Deanship of Scientific Research, Imam Mohammad Ibn Saud Islamic University (IMSIU) Riyadh 13317 Saudi Arabia.
Lina M AlnegheryDepartment of Biology, College of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU) Riyadh 11623 Saudi Arabia.
Ali M AlaseemDepartment of Pharmacology, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU) Riyadh 13317 Saudi Arabia.
Mohamed G El-DesoukyEgyptian Propylene and Polypropylene Company Port Said 42511 Egypt.ORCID https://orcid.org/0000-0001-6060-463X
Ashraf A El-BindaryHealth Sciences Research Center (HSRC), Deanship of Scientific Research, Imam Mohammad Ibn Saud Islamic University (IMSIU) Riyadh 13317 Saudi Arabia.ORCID https://orcid.org/0000-0002-4494-3436

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metal-organic frameworks (MOFs) have become significant nanocarriers for drug delivery owing to their remarkable high surface area, adjustable porosity, and functional adaptability. This research focused on developing a multifunctional pH-responsive delivery system by encapsulating doxorubicin (DOX) within a lanthanum-based MOF (La-MOF) and integrating this complex into a biocompatible electrospun nanofiber membrane made of polycaprolactone (PCL) and chitosan (CS). The resulting DOX@La-MOF/CS-PCL nanofiber membrane was created by means of a one-step electrospinning technique and extensively analyzed using XRD, FTIR, XPS, SEM, EDX, and BET techniques to confirm its structural honesty, surface morphology, and chemical makeup. Drug release experiments indicated a dual-responsive behavior, demonstrating much higher DOX release at body temperature (37 °C) and in acidic environment (pH 5.0) that mimic the tumor micro environment. According to kinetic analysis, diffusion and erosion worked together to affect the release mechanism, which is consistent with zero-order, first-order, Korsmeyer-Peppas, as well as Higuchi models.

Identifiers

PMID41384078
PMCPMC12691353

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.